Cargando…

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients

BACKGROUND: Thyroid eye disease (TED) is an autoimmune inflammatory process that can lead to eye-bulging (proptosis) and double-vision (diplopia). Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, has demonstrated improvements in proptosis and diplopia. Thyroid dysregulatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Terry J, Choudhary, Chitra, Bhattacharya, Rajib J, Holt, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627953/ http://dx.doi.org/10.1210/jendso/bvac150.1780

Ejemplares similares

PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

SAT461 Hearing-related Issues Associated With Graves’ Disease, Thyroid Eye Disease And Treatment With Teprotumumab
por: Smith, Terry J, et al.
Publicado: (2023)

RF35 | PSAT257 The Severity of Subacute Thyroiditis Depends on Its Causative Agent
por: Brancatella, Alessandro, et al.
Publicado: (2022)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
por: Mohamed, Abubakr, et al.
Publicado: (2022)

RF35 | PSAT298 Subacute Thyroiditis Following SARS-CoV-2 mRNA Vaccine
por: Pandey, Shanta, et al.
Publicado: (2022)

PSAT380 Characteristics and prognosis of Differentiated Thyroid Cancer in patients with Graves Disease
por: Panthi, Sujata, et al.
Publicado: (2022)

PSAT355 A Case Report Identifying Graves’ Ophthalmopathy in a Myasthenia Gravis Crisis and Response to Teprotumumab
por: Zia, Abdul, et al.
Publicado: (2022)

RF35 | PSAT269 Double-Blind, Randomized, Placebo-controlled, Multicenter, Phase 2b Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Kahaly, George, et al.
Publicado: (2022)

SAT471 Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials
por: Smith, Terry J, et al.
Publicado: (2023)

PSAT362 Hypothyroidism Associated Colonic Rupture
por: Seetharaman, Karthik, et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

SAT-554 Teprotumumab in Graves' Orbitopathy: Extended Outcome Analyses
por: Kahaly, George, et al.
Publicado: (2019)

OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
por: Kahaly, George J, et al.
Publicado: (2020)

PSAT329 A Delayed Diagnosis of Subclinical Hypothyroidism Due to Interferences with Thyroid Function Immunoassays
por: Khine, Aye, et al.
Publicado: (2022)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

RF23 | PSAT300 The Curious Case of Abnormal Thyroid Function Tests: Think Streptavidin Interference
por: Kodali, Alimitha M, et al.
Publicado: (2022)

RF23 | PSAT240 Suboptimal Thyroid Hormone Replacement is Associated with Worse Hospital Outcomes
por: Bianco, Antonio C, et al.
Publicado: (2022)

RF11 | PSAT249 Radiofrequency Ablation for Thyroid Nodules: The First Ecuadorian Prospective Cohort
por: Naranjo, Eddy P Lincango, et al.
Publicado: (2022)

PSAT327 Can Cannabis Use Lead to Central Hypothyroidism
por: Farasat, Sadaf, et al.
Publicado: (2022)

PSAT328 Primary Hypothyroidism Presenting with Galactorrhea and Pituitary Hyperplasia
por: Akkireddy, Padmaja, et al.
Publicado: (2022)

FRI554 Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab
por: Marta Niedzialkowska, Ewelina, et al.
Publicado: (2023)

RF11 | PSAT272 Suppressive Tumor Immune Microenvironment is Associated with Aggressive Differentiated Thyroid Cancer
por: Kotwal, Anupam, et al.
Publicado: (2022)

PSAT253 Differentiation of Pituitary Hyperplasia From Adenoma in the Setting of Severe Hypothyroidism
por: Gun, Zubeyir Hasan, et al.
Publicado: (2022)

RF23 | PSAT301 Plasmapheresis and Extracorporeal Membrane Oxygenation (ECMO) for Treatment of Thyroid Storm with Multiorgan Failure
por: Chugh, Radhika, et al.
Publicado: (2022)

RF35 | PSAT262 Comparative Study of Hertel Exophthalmometer and Luedde Exophthalmometer Versus Computed Tomography for Measurement of Proptosis in Normal Subjects
por: Traiwanatham, Sirinapa, et al.
Publicado: (2022)

OR11-4 Teprotumumab Markedly Improves Disease-related Quality of Life: Lessons From Two Randomized, Placebo-controlled Trials
por: Douglas, Raymond S, et al.
Publicado: (2022)

PSAT293 Uncommon Presentation of Hashimoto Thyroiditis
por: Alzenaidi, Ahlam
Publicado: (2022)

SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED)
por: Xin, Yan, et al.
Publicado: (2020)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

PSAT346 Persistent Fluctuation Between Hypothyroidism and Hyperthyroidism in a Patient with Both Hashimoto's Thyroiditis and Graves’ Disease: Challenges in Diagnosis and Treatment Approach
por: Verma, Vipin, et al.
Publicado: (2022)

PSAT351 Thyroiditis following COVID-19 vaccination
por: Choksi, Palak, et al.
Publicado: (2022)

PSAT342 Hypothyroidism After Use Of Immune Checkpoint Inhibitor Therapy In Patient With Graves’ Disease
por: Sharma, Rajeev
Publicado: (2022)

PSAT251 Examination of TRH test in Central Hypothyroidism due to Non-Functional Pituitary Adenoma
por: Buyandalai, Battsetseg, et al.
Publicado: (2022)

PSAT348 Falsely Elevated TSI Antibody Without Causing Hyperthyroidism, in a Hypothyroid Patient
por: Anto Antony, Mc, et al.
Publicado: (2022)

SAT455 A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial To Evaluate The Efficacy And Safety Of Teprotumumab In Patients With Chronic (Inactive/Low CAS) Thyroid Eye Disease
por: Douglas, Raymond S, et al.
Publicado: (2023)

RF11 | PSAT234 Deep learning analysis of thyroid nodule ultrasound images has high sensitivity and negative predictive value to rule-out thyroid cancer
por: Clark, Toshimasa, et al.
Publicado: (2022)

SAT459 Teprotumumab Pooled Efficacy From The European Study Sites Participating In The Phase 2, OPTIC (Phase 3) And OPTIC-X Pivotal Trials
por: Kahaly, George J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hrvkj2mnovdut3r7b4khqcujmr